DUS1L

Summary

DUS1L (dihydrouridine synthase 1 like, HGNC:30086) is a protein-coding gene on chromosome 17q25.3, encoding tRNA-dihydrouridine(16/17) synthase [NAD(P)(+)]-like (Q6P1R4). Catalyzes the synthesis of dihydrouridine, a modified base found in the D-loop of most tRNAs.

Enables tRNA-dihydrouridine16 synthase activity and tRNA-dihydrouridine17 synthase activity. Involved in tRNA dihydrouridine synthesis. Located in cytoplasm and nucleus.

Source: NCBI Gene 64118 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 95 total — 1 pathogenic, 1 likely-pathogenic
• Phenotypes (HPO): 1
• MANE Select transcript: NM_022156

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30086
Approved symbol	DUS1L
Name	dihydrouridine synthase 1 like
Location	17q25.3
Locus type	gene with protein product
Status	Approved
Aliases	PP3111, DUS1
Ensembl gene	ENSG00000169718
Ensembl biotype	protein_coding
OMIM	621087
Entrez	64118

Gene structure

Transcript identifiers

Ensembl transcripts: 25 — 18 protein_coding, 6 retained_intron, 1 nonsense_mediated_decay

ENST00000306796, ENST00000354321, ENST00000538833, ENST00000542088, ENST00000577574, ENST00000577907, ENST00000578176, ENST00000578264, ENST00000578428, ENST00000578846, ENST00000578907, ENST00000579854, ENST00000580731, ENST00000582407, ENST00000582529, ENST00000584871, ENST00000909424, ENST00000909425, ENST00000909426, ENST00000950985, ENST00000950986, ENST00000950987, ENST00000950988, ENST00000950989, ENST00000950990

RefSeq mRNA: 1 — MANE Select: NM_022156 NM_022156

CCDS: CCDS32775

Canonical transcript exons

ENST00000306796 — 14 exons

Exon	Start	End
ENSE00001163585	82060865	82060961
ENSE00001314670	82061618	82061721
ENSE00001506713	82060701	82060783
ENSE00002276058	82064823	82065069
ENSE00002483443	82064126	82064234
ENSE00002695285	82065613	82065804
ENSE00002708235	82057506	82058254
ENSE00003498428	82058781	82058818
ENSE00003499794	82063468	82063518
ENSE00003533938	82062861	82062973
ENSE00003559329	82061901	82061983
ENSE00003591147	82058341	82058416
ENSE00003626548	82061209	82061353
ENSE00003685565	82059948	82060093

Expression profiles

Bgee: expression breadth ubiquitous, 276 present calls, max score 98.49.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 27.4167 / max 401.6199, expressed in 1815 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
168900	27.2386	1814
168898	0.0755	14
168897	0.0631	15
168899	0.0394	8

Top tissues by expression

288 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
lower esophagus mucosa	UBERON:0035834	98.49	gold quality
body of pancreas	UBERON:0001150	98.22	gold quality
mucosa of transverse colon	UBERON:0004991	98.03	gold quality
body of stomach	UBERON:0001161	97.99	gold quality
right lobe of liver	UBERON:0001114	97.98	gold quality
apex of heart	UBERON:0002098	97.81	gold quality
granulocyte	CL:0000094	97.75	gold quality
skin of abdomen	UBERON:0001416	97.68	gold quality
skin of leg	UBERON:0001511	97.66	gold quality
minor salivary gland	UBERON:0001830	97.64	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	97.62	gold quality
adenohypophysis	UBERON:0002196	97.57	gold quality
right lobe of thyroid gland	UBERON:0001119	97.56	gold quality
transverse colon	UBERON:0001157	97.51	gold quality
small intestine Peyer’s patch	UBERON:0003454	97.44	gold quality
left lobe of thyroid gland	UBERON:0001120	97.41	gold quality
right testis	UBERON:0004534	97.40	gold quality
left testis	UBERON:0004533	97.39	gold quality
saliva-secreting gland	UBERON:0001044	97.35	gold quality
metanephros cortex	UBERON:0010533	97.34	gold quality
gastrocnemius	UBERON:0001388	97.27	gold quality
left uterine tube	UBERON:0001303	97.17	gold quality
mucosa of stomach	UBERON:0001199	97.08	gold quality
spleen	UBERON:0002106	96.93	gold quality
esophagus mucosa	UBERON:0002469	96.88	gold quality
pituitary gland	UBERON:0000007	96.85	gold quality
right uterine tube	UBERON:0001302	96.83	gold quality
endocervix	UBERON:0000458	96.80	gold quality
muscle layer of sigmoid colon	UBERON:0035805	96.80	gold quality
parotid gland	UBERON:0001831	96.76	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	8.24

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

26 targeting DUS1L, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-1184	99.99	68.19	1458
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-103A-3P	99.98	69.14	1595
HSA-MIR-107	99.98	69.14	1595
HSA-MIR-507	99.97	70.11	1915
HSA-MIR-557	99.96	70.01	1640
HSA-MIR-3910	99.95	71.13	2227
HSA-MIR-345-3P	99.89	70.23	1421
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-4319	99.76	69.83	2586
HSA-MIR-670-5P	99.67	69.94	1565
HSA-MIR-203A-3P	99.49	70.56	2806
HSA-MIR-125A-5P	99.36	70.59	1640
HSA-MIR-125B-5P	99.36	70.36	1662
HSA-MIR-6852-5P	99.17	66.69	2073
HSA-MIR-7160-5P	99.11	67.17	2207
HSA-MIR-5701	98.97	69.54	1502
HSA-MIR-3938	98.72	66.07	834
HSA-MIR-4722-5P	98.46	66.34	1611
HSA-MIR-4768-3P	98.16	66.02	2330
HSA-MIR-562	97.66	65.63	698
HSA-MIR-4732-3P	97.15	65.45	881
HSA-MIR-6872-5P	95.60	67.57	55
HSA-MIR-6814-3P	93.66	66.98	50
HSA-MIR-1268A	87.06	61.46	145
HSA-MIR-1268B	87.06	61.46	145

Literature-anchored findings (GeneRIF, showing 1)

• Human DUS1L catalyzes dihydrouridine modification at tRNA positions 16/17, and DUS1L overexpression perturbs translation. (PMID:39354220)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	dus1l	ENSDARG00000089260
mus_musculus	Dus1l	ENSMUSG00000025155
rattus_norvegicus	Dus1l	ENSRNOG00000047905
drosophila_melanogaster	Dus1	FBGN0031238
caenorhabditis_elegans	F36A2.2	WBGENE00009452

Paralogs (3): DUS4L (ENSG00000105865), DUS3L (ENSG00000141994), DUS2 (ENSG00000167264)

Protein

Protein identifiers

tRNA-dihydrouridine(16/17) synthase [NAD(P)(+)]-like — Q6P1R4 (reviewed: Q6P1R4)

Alternative names: tRNA-dihydrouridine synthase 1-like

All UniProt accessions (9): F5H0Q0, H0YGW8, J3KSK2, J3KT57, J3QKP9, J3QLE4, J3QQL9, Q6P1R4, J3QQZ0

UniProt curated annotations — full annotation on UniProt →

Function. Catalyzes the synthesis of dihydrouridine, a modified base found in the D-loop of most tRNAs. Specifically modifies U16 and U17 in cytoplasmic tRNAs. Affects the level of some mature tRNA and thereby the total cellular translation.

Subcellular location. Cytoplasm. Nucleus.

Similarity. Belongs to the Dus family. Dus1 subfamily.

RefSeq proteins (1): NP_071439* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR013785	Aldolase_TIM	Homologous_superfamily
IPR018517	tRNA_hU_synthase_CS	Conserved_site
IPR035587	DUS-like_FMN-bd	Domain

Pfam: PF01207

Catalyzed reactions (Rhea), 4 shown:

• 5,6-dihydrouridine(17) in tRNA + NADP(+) = uridine(17) in tRNA + NADPH + H(+) (RHEA:53368)
• 5,6-dihydrouridine(17) in tRNA + NAD(+) = uridine(17) in tRNA + NADH + H(+) (RHEA:53372)
• 5,6-dihydrouridine(16) in tRNA + NADP(+) = uridine(16) in tRNA + NADPH + H(+) (RHEA:53376)
• 5,6-dihydrouridine(16) in tRNA + NAD(+) = uridine(16) in tRNA + NADH + H(+) (RHEA:53380)

UniProt features (13 total): binding site 6, region of interest 2, compositionally biased region 2, chain 1, mutagenesis site 1, active site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6P1R4-F1	87.95	0.74

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 108 (proton donor)

Ligand- & substrate-binding residues (6): 208–210; 232–233; 23–25; 79; 147; 175

Mutagenesis-validated functional residues (1):

Position	Phenotype
108	abolishes cell growth.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 146 (showing top): GOMF_OXIDOREDUCTASE_ACTIVITY_ACTING_ON_THE_CH_CH_GROUP_OF_DONORS, GOBP_TRNA_METABOLIC_PROCESS, GOBP_RNA_MODIFICATION, MARTINEZ_RB1_TARGETS_DN, SPIELMAN_LYMPHOBLAST_EUROPEAN_VS_ASIAN_UP, NIKOLSKY_BREAST_CANCER_17Q21_Q25_AMPLICON, GOBP_TRNA_PROCESSING, GOBP_TRNA_MODIFICATION, PARENT_MTOR_SIGNALING_UP, LIU_SOX4_TARGETS_DN, GOMF_OXIDOREDUCTASE_ACTIVITY_ACTING_ON_THE_CH_CH_GROUP_OF_DONORS_NAD_OR_NADP_AS_ACCEPTOR, GOMF_FLAVIN_ADENINE_DINUCLEOTIDE_BINDING, COULOUARN_TEMPORAL_TGFB1_SIGNATURE_DN, YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_11, LI_DCP2_BOUND_MRNA

GO Biological Process (2): tRNA dihydrouridine synthesis (GO:0002943), tRNA processing (GO:0008033)

GO Molecular Function (7): tRNA dihydrouridine synthase activity (GO:0017150), flavin adenine dinucleotide binding (GO:0050660), tRNA-dihydrouridine16 synthase activity (GO:0102262), tRNA-dihydrouridine17 synthase activity (GO:0102263), nucleotide binding (GO:0000166), protein binding (GO:0005515), oxidoreductase activity (GO:0016491)

GO Cellular Component (2): nucleus (GO:0005634), cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
tRNA dihydrouridine synthase activity	2
tRNA modification	1
RNA processing	1
tRNA metabolic process	1
tRNA dihydrouridine synthesis	1
RNA dihydrouridine synthase activity	1
catalytic activity, acting on a tRNA	1
nucleotide binding	1
anion binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
binding	1
catalytic activity	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1876 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
DUS1L	TRMT61A	Q96FX7	582
DUS1L	METTL1	Q9UBP6	525
DUS1L	TRMT10A	Q8TBZ6	524
DUS1L	TRMT1	Q9NXH9	486
DUS1L	TRMT5	Q32P41	464
DUS1L	WDR4	P57081	464
DUS1L	TRMT6	Q9UJA5	463
DUS1L	TRMT11	Q7Z4G4	444
DUS1L	NSUN2	Q08J23	427
DUS1L	PUS7	Q96PZ0	421
DUS1L	CCDC90B	Q9GZT6	411
DUS1L	DUS3L	Q96G46	386
DUS1L	DUS2	Q9NX74	384
DUS1L	TRMT44	Q8IYL2	377
DUS1L	TRMT2B	Q96GJ1	376

IntAct

20 interactions, top by confidence:

A	B	Type	Score
MEOX2	DUS1L	psi-mi:“MI:0915”(physical association)	0.560
CAMK2B	DUS1L	psi-mi:“MI:0915”(physical association)	0.560
CAMK2G	DUS1L	psi-mi:“MI:0915”(physical association)	0.560
FLAD1	UBAP2	psi-mi:“MI:0914”(association)	0.560
CCT6A	TXNDC9	psi-mi:“MI:0914”(association)	0.530
DUS1L	DAPK1	psi-mi:“MI:0407”(direct interaction)	0.440
DUS1L	SRPK1	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
ECE1	DUS1L	psi-mi:“MI:0915”(physical association)	0.370
HJURP		psi-mi:“MI:0914”(association)	0.350
SSB	RPS3A	psi-mi:“MI:0914”(association)	0.350
FOXD3	CLUH	psi-mi:“MI:0914”(association)	0.350
HRAS	IGKV2D-24	psi-mi:“MI:0914”(association)	0.350
HRAS	IGHV1-45	psi-mi:“MI:0914”(association)	0.350
DUS1L	MEOX2	psi-mi:“MI:0915”(physical association)	0.000
DUS1L	CAMK2B	psi-mi:“MI:0915”(physical association)	0.000
DUS1L	CAMK2G	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (18): DUS1L (Affinity Capture-MS), DUS1L (Affinity Capture-MS), DUS1L (Reconstituted Complex), DUS1L (Two-hybrid), DUS1L (Two-hybrid), DUS1L (Two-hybrid), DUS1L (Affinity Capture-MS), DUS1L (Reconstituted Complex), DUS1L (Affinity Capture-MS), DUS1L (Affinity Capture-MS), DUS1L (Affinity Capture-MS), DUS1L (Affinity Capture-MS), DUS1L (Affinity Capture-MS), DUS1L (Co-fractionation), THUMPD2 (Co-fractionation)

ESM2 similar proteins: A1CJ34, A2QY22, A8MPP1, B3NSW1, B4GU19, B4I0K4, B4L1Z2, B4M891, B4NDG5, B4PZB4, F1R345, O00329, O12944, P38935, P40694, P70270, Q1E5T3, Q21489, Q24087, Q29FS3, Q2U587, Q3B7N1, Q4R4T6, Q5M9G7, Q5ZKD7, Q5ZLG3, Q642T7, Q68CQ4, Q6AXC6, Q6P1R4, Q6PEH4, Q750G3, Q7QEI1, Q7SXA9, Q7ZU90, Q80Y81, Q86WJ1, Q8BTT6, Q8C2P3, Q8CGS5

Diamond homologs: A3LUK5, A5DBS1, O25427, O27281, O52532, O52533, O52536, O52539, O67533, O68273, O83945, O95620, P0A2R6, P0A2R7, P0ABT5, P0ABT6, P0ABT7, P0CN28, P0CN29, P33371, P37567, P41504, P44606, P44965, P45672, P9WNS6, P9WNS7, Q06063, Q08111, Q09504, Q1RH84, Q28BT8, Q3KRC5, Q3SWF0, Q4UNJ4, Q50049, Q54CU9, Q55724, Q68XZ3, Q6CWM0

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

95 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	1
Uncertain significance	77
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
2425655	NC_000017.10:g.(?79891090)(80333370_?)del	Pathogenic
3383376	NM_022156.5(DUS1L):c.896del (p.Glu299fs)	Likely pathogenic

SpliceAI

2524 predictions. Top by Δscore:

Variant	Effect	Δscore
17:82058819:C:CC	acceptor_gain	1.0000
17:82059942:ACTT:A	donor_loss	1.0000
17:82059943:CTTA:C	donor_loss	1.0000
17:82059944:TTA:T	donor_loss	1.0000
17:82059945:TACGC:T	donor_loss	1.0000
17:82059946:A:AC	donor_gain	1.0000
17:82059946:ACG:A	donor_gain	1.0000
17:82059947:C:CA	donor_gain	1.0000
17:82059947:CG:C	donor_gain	1.0000
17:82059947:CGC:C	donor_gain	1.0000
17:82059947:CGCT:C	donor_gain	1.0000
17:82059947:CGCTT:C	donor_gain	1.0000
17:82060876:G:C	donor_gain	1.0000
17:82061202:AACTC:A	donor_loss	1.0000
17:82061203:ACT:A	donor_loss	1.0000
17:82061204:CTC:C	donor_loss	1.0000
17:82061205:TCACG:T	donor_loss	1.0000
17:82061206:CA:C	donor_loss	1.0000
17:82061207:A:AC	donor_gain	1.0000
17:82061208:C:CC	donor_gain	1.0000
17:82061208:CG:C	donor_gain	1.0000
17:82061208:CGT:C	donor_gain	1.0000
17:82061208:CGTG:C	donor_gain	1.0000
17:82061208:CGTGT:C	donor_gain	1.0000
17:82061349:GCCCT:G	acceptor_gain	1.0000
17:82061350:CCCT:C	acceptor_gain	1.0000
17:82061350:CCCTC:C	acceptor_gain	1.0000
17:82061351:CCT:C	acceptor_gain	1.0000
17:82061351:CCTC:C	acceptor_gain	1.0000
17:82061352:CT:C	acceptor_gain	1.0000

AlphaMissense

3084 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:82058347:A:G	C426R	1.000
17:82058392:A:G	C411R	1.000
17:82058407:A:G	C406R	1.000
17:82064134:G:T	A113D	1.000
17:82058345:G:C	C426W	0.999
17:82058346:C:G	C426S	0.999
17:82058346:C:T	C426Y	0.999
17:82058347:A:T	C426S	0.999
17:82058378:G:C	C415W	0.999
17:82058379:C:G	C415S	0.999
17:82058379:C:T	C415Y	0.999
17:82058380:A:G	C415R	0.999
17:82058380:A:T	C415S	0.999
17:82058390:G:C	C411W	0.999
17:82058391:C:G	C411S	0.999
17:82058391:C:T	C411Y	0.999
17:82058392:A:T	C411S	0.999
17:82058406:C:G	C406S	0.999
17:82058406:C:T	C406Y	0.999
17:82058407:A:T	C406S	0.999
17:82058795:A:G	C398R	0.999
17:82058803:C:G	C395S	0.999
17:82058804:A:G	C395R	0.999
17:82058804:A:T	C395S	0.999
17:82061226:G:C	F275L	0.999
17:82061226:G:T	F275L	0.999
17:82061228:A:G	F275L	0.999
17:82061234:G:C	H273D	0.999
17:82061964:C:G	R177P	0.999
17:82062930:T:A	K147N	0.999

dbSNP variants (sampled 300 via entrez): RS1000871419 (17:82065975 G>A), RS1000903772 (17:82065025 C>A,T), RS1001096022 (17:82065260 C>A,T), RS10013 (17:82057352 C>G), RS1001435731 (17:82059088 T>C), RS1001618553 (17:82059409 G>A), RS1002170531 (17:82060254 G>A,C), RS1002226659 (17:82065520 A>C), RS1002369018 (17:82065259 T>A), RS1002840197 (17:82062571 T>A), RS1003127682 (17:82062043 T>A,C), RS1003262731 (17:82067294 C>T), RS1003461114 (17:82061473 G>A), RS1003533498 (17:82062808 C>T), RS1003589158 (17:82061283 A>G)

Disease associations

OMIM: gene MIM:621087 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): microcephaly (MONDO:0001149)

Orphanet (0):

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0000252	Microcephaly

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST008862_5	Triacylglycerol 56:6 levels	7.000000e-07
GCST010002_133	Refractive error	2.000000e-50

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004530	triglyceride measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D008831	Microcephaly	C05.660.207.620; C10.500.507.400.500; C16.131.621.207.620; C16.131.666.507.400.500

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

29 total (human), top 29 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases expression, decreases expression, affects cotreatment, increases abundance	4
Arsenic	increases abundance, increases expression, affects cotreatment	2
bisphenol F	increases expression	1
triphenyl phosphate	affects expression	1
propylparaben	increases expression	1
bisphenol A	increases expression	1
lead acetate	increases expression	1
beta-lapachone	decreases expression	1
methylparaben	increases expression	1
cobaltous chloride	decreases expression	1
cupric chloride	increases expression	1
K 7174	decreases expression	1
bisphenol S	increases expression	1
Sunitinib	increases expression	1
Benzo(a)pyrene	increases methylation	1
Gasoline	affects cotreatment, increases abundance, increases expression	1
Phthalic Acids	increases methylation	1
Polycyclic Aromatic Hydrocarbons	affects cotreatment, increases abundance, increases expression	1
Smoke	decreases expression	1
Thiram	decreases expression	1
Tobacco Smoke Pollution	increases expression	1
Tretinoin	decreases expression	1
Valproic Acid	increases methylation	1
Cyclosporine	decreases expression	1
Copper Sulfate	decreases expression	1
Lactic Acid	decreases expression	1
1-Butanol	affects cotreatment, increases abundance, increases expression	1
Acrylamide	decreases expression	1
Particulate Matter	affects cotreatment, increases abundance, increases expression	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_E0TZ	Ubigene Hep G2 DUS1L KO	Cancer cell line	Male

Clinical trials (associated diseases)

17 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT05518188	PHASE1/PHASE2	RECRUITING	Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt)
NCT00001639	Not specified	COMPLETED	Evaluation of Patients With Unresolved Chromosome Abnormalities
NCT01151462	Not specified	WITHDRAWN	Postnatal HCMV Infection in Very Preterm Infants. Implications, Morbidity, Growth and Neurodevelopmental Outcomes.
NCT01565005	Not specified	COMPLETED	Microcephaly Genetic Deficiency in Neural Progenitors
NCT02510170	Not specified	COMPLETED	Fetal and Maternal Head Circumference During Pregnancy in Israeli Population
NCT02741882	Not specified	COMPLETED	Zika and Microcephaly: Case-control Study
NCT02943304	Not specified	COMPLETED	Neurodevelopment Outcome of Newborns Exposed to Zika Virus (ZIKV) in Utero
NCT03255369	Not specified	UNKNOWN	Vertical Exposure to Zika Virus and Its Consequences for Child Neurodevelopment (ZIKVIRUSIFF)
NCT03325946	Not specified	RECRUITING	The FBRI VTC Neuromotor Research Clinic
NCT03330600	Not specified	COMPLETED	Efficacy of Aquatic Physiotherapy in Children With Microcephaly by Zika Virus Congenital Syndrome
NCT03548779	Not specified	COMPLETED	North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2
NCT03651687	Not specified	COMPLETED	Guangzhou Surveillance and Clinical Study in Microcephaly (GSCSM)
NCT03922594	Not specified	TERMINATED	Surveillance of Zika-related Microcephaly in Sub-Saharan Africa and Asia
NCT04816175	Not specified	COMPLETED	Intensive Therapy for Children With Microcephaly, Hyperkinetic Movements, or Global Developmental Delay
NCT05322980	Not specified	COMPLETED	Summary of Infants Weighing 500 Grams or Less
NCT06019182	Not specified	RECRUITING	MEHMO Natural History and Biomarkers
NCT06566066	Not specified	RECRUITING	Register for Patients With Thyroid Hormone Resistance.